27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Johnson & Johnson (NYSE:JNJ) said Tuesday that the European rollout of its COVID-19 vaccine is set to continue after it got the go-ahead from the regulator on the continent.
What Happened: The multinational pharmaceutical giant said in a statement that the European Medical Agency’s Pharmacovigilance Risk Assessment Committee had given updated guidance for the use of its COVID-19 vaccine.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The EMA said that the “overall benefit-risk profile remains positive.”
The guidance comes after the PRAC reviewed a “small number of cases of a very rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the Company's COVID-19 vaccine,” said Johnson & Johnson.
As a result of the guidance, Johnson & Johnson will update the vaccine’s Summary of Product Characteristics and Package Leaflet to include information on diagnosis and management of adverse effects.
Why It Matters: Johnson & Johnson said it will resume the shipment of the vaccine in the European Union, Norway and Iceland.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
In the United States, authorities in multiple states halted the distribution of Johnson & Johnson’s vaccine due to concerns about adverse reactions earlier in the month.
Last week, the company’s stock fell — leading to buying by bulls — after the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration recommended that the use of Johnson & Johnson’s COVID-19 vaccine be paused in the country.
See Also: US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca
This month, the EMA concluded that there are possible links between the COVID-19 vaccine made by AstraZeneca Plc (NYSE:AZN) and blood clots. The agency said these should be listed as a “very rare side effect.”
On Tuesday, Johnson & Johnson reported $100 million in COVID-19 vaccine sales and better than expected Q1 earnings of $2.59 per share, up 12.6% on a year-over-year basis. The earnings beat estimates of $2.34 per share.
Price Action: Johnson and Johnson shares closed 2.33% higher at $166.48 on Tuesday and fell 0.2% in the after-hours trading.
For news coverage in Italian or Spanish, check out Benzinga Italia and Benzinga España.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.